Kringle Pharma (TSE:4884) Net Margin %: -1,732.60% (As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
40 GF Score
Price 円318.00
GF Value 円497.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Net Margin %?

Kringle Pharma TSE:4884 +2.91% 40 Net Margin % is -1,732.60% as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円497.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Kringle Pharma ranks worse than 80.44% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Kringle Pharma's Net Income for the three months ended in Mar. 2026 was 円-314.75 Mil. Kringle Pharma's Revenue for the three months ended in Mar. 2026 was 円18.17 Mil. Therefore, Kringle Pharma's net margin for the quarter that ended in Mar. 2026 was -1,732.60%.

The historical rank and industry rank for Kringle Pharma's Net Margin % or its related term are showing as below:

TSE:4884' s Net Margin % Range Over the Past 10 Years
Min: -1268.79   Med: -524.53   Max: -25.2
Current: -1260.37

TSE:4884's Net Margin % is ranked worse than
80.44% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs TSE:4884: -1260.37

Kringle Pharma  (TSE:4884) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Kringle Pharma Net Margin % Related Terms

Kringle Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Net Margin % Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Net Margin %
Get a 7-Day Free Trial -103.94 -84.69 -1,233.43 -945.12 -1,268.79

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1,263.52 -964.82 -1,086.97 -1,732.60

TSE:4884 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Kringle Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kringle Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kringle Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kringle Pharma's Net Margin % falls into.


TSE:4884
40GF Score
Kringle Pharma Inc TSE:4884
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kringle Pharma's Net Margin for the fiscal year that ended in Sep. 2025 is calculated as

Net Margin=Net Income (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-916.255/72.215
=-1,268.79 %

Kringle Pharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-314.745/18.166
=-1,732.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,732.60% mean?
Kringle Pharma (TSE:4884) has a Net Margin % of -1,732.60% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #761 out of 946 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Kringle Pharma's Net Margin % too high?
Kringle Pharma's current Net Margin % is -1,732.60%. Based on the distribution chart, Kringle Pharma ranks #761 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #761 out of 946 companies for Net Margin %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Net Margin % is -1,732.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current Net Margin % is -1,732.60%. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Net Margin % is -1,732.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Net Margin %: -1,732.60%
  • GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score

Get the complete analysis for TSE:4884

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円318.00
Price
円497.82
GF Value